ID   BRCA1_MOUSE             Reviewed;        1812 AA.
AC   P48754; A2A4Q4; Q60957; Q60983;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2012, sequence version 3.
DT   18-JUN-2025, entry version 221.
DE   RecName: Full=Breast cancer type 1 susceptibility protein homolog;
DE            EC=2.3.2.27 {ECO:0000250|UniProtKB:P38398};
DE   AltName: Full=RING-type E3 ubiquitin transferase BRCA1 {ECO:0000305};
GN   Name=Brca1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Embryo;
RX   PubMed=8634697; DOI=10.1093/hmg/4.12.2265;
RA   Abel K.J., Xy J., Yin G.Y., Lyons R.H., Meisler M.H., Weber B.L.;
RT   "Mouse Brca1: localization sequence analysis and identification of
RT   evolutionarily conserved domains.";
RL   Hum. Mol. Genet. 4:2265-2273(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=8634698; DOI=10.1093/hmg/4.12.2275;
RA   Sharan S.K., Wims M., Bradley A.;
RT   "Murine Brca1: sequence and significance for human missense mutations.";
RL   Hum. Mol. Genet. 4:2275-2278(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=129/SvJ;
RX   PubMed=8575748; DOI=10.1006/geno.1995.9963;
RA   Bennett L.M., Haugen-Strano A., Cochran C., Brownlee H.A.,
RA   Fiedorek F.T. Jr., Wiseman R.W.;
RT   "Isolation of the mouse homologue of BRCA1 and genetic mapping to mouse
RT   chromosome 11.";
RL   Genomics 29:576-581(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=129/SvJ; TISSUE=Embryo;
RX   PubMed=7590247; DOI=10.1101/gad.9.21.2712;
RA   Lane T.F., Deng C., Elson A., Lyu M.S., Kozak C.A., Leder P.;
RT   "Expression of Brca1 is associated with terminal differentiation of
RT   ectodermally and mesodermally derived tissues in mice.";
RL   Genes Dev. 9:2712-2722(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 727-1111.
RC   STRAIN=C57BL/6J; TISSUE=Embryo;
RX   PubMed=7550308; DOI=10.1038/ng0995-17;
RA   Marquis S.T., Rajan J.V., Wynshaw-Boris A., Xu J., Yin G.Y., Abel K.J.,
RA   Weber B.L., Chodosh L.A.;
RT   "The developmental pattern of Brca1 expression implies a role in
RT   differentiation of the breast and other tissues.";
RL   Nat. Genet. 11:17-26(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 789-1250.
RC   STRAIN=129/SvJ;
RX   PubMed=8566965; DOI=10.1007/bf02265277;
RA   Schroeck E., Badger P., Larson D., Erdos M., Wynshaw-Boris A., Ried T.,
RA   Brody L.;
RT   "The murine homolog of the human breast and ovarian cancer susceptibility
RT   gene Brca1 maps to mouse chromosome 11D.";
RL   Hum. Genet. 97:256-259(1996).
RN   [8]
RP   INTERACTION WITH ACACA.
RX   PubMed=12360400; DOI=10.1038/sj.onc.1205915;
RA   Magnard C., Bachelier R., Vincent A., Jaquinod M., Kieffer S., Lenoir G.M.,
RA   Venezia N.D.;
RT   "BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT
RT   domains.";
RL   Oncogene 21:6729-6739(2002).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-831, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic fibroblast;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-706 AND SER-717, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Lung, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=23039116; DOI=10.1111/gtc.12005;
RA   Kogo H., Tsutsumi M., Inagaki H., Ohye T., Kiyonari H., Kurahashi H.;
RT   "HORMAD2 is essential for synapsis surveillance during meiotic prophase via
RT   the recruitment of ATR activity.";
RL   Genes Cells 17:897-912(2012).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22549958; DOI=10.1101/gad.187559.112;
RA   Wojtasz L., Cloutier J.M., Baumann M., Daniel K., Varga J., Fu J.,
RA   Anastassiadis K., Stewart A.F., Remenyi A., Turner J.M., Toth A.;
RT   "Meiotic DNA double-strand breaks and chromosome asynapsis in mice are
RT   monitored by distinct HORMAD2-independent and -dependent mechanisms.";
RL   Genes Dev. 26:958-973(2012).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that specifically mediates the
CC       formation of 'Lys-6'-linked polyubiquitin chains and plays a central
CC       role in DNA repair by facilitating cellular responses to DNA damage. It
CC       is unclear whether it also mediates the formation of other types of
CC       polyubiquitin chains. The BRCA1-BARD1 heterodimer coordinates a diverse
CC       range of cellular pathways such as DNA damage repair, ubiquitination
CC       and transcriptional regulation to maintain genomic stability. Regulates
CC       centrosomal microtubule nucleation. Required for appropriate cell cycle
CC       arrests after ionizing irradiation in both the S-phase and the G2 phase
CC       of the cell cycle. Required for FANCD2 targeting to sites of DNA
CC       damage. Inhibits lipid synthesis by binding to inactive phosphorylated
CC       ACACA and preventing its dephosphorylation. Contributes to homologous
CC       recombination repair (HRR) via its direct interaction with PALB2, fine-
CC       tunes recombinational repair partly through its modulatory role in the
CC       PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks.
CC       Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation
CC       and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-
CC       mediated ubiquitination of RBBP8. Acts as a transcriptional activator.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000250|UniProtKB:P38398};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Heterodimer with BARD1. Part of the BRCA1-associated genome
CC       surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1,
CC       ATM, BLM, PMS2 and the MRE11-RAD50-NBN protein (MRN) complex. This
CC       association could be a dynamic process changing throughout the cell
CC       cycle and within subnuclear domains. Component of the BRCA1-A complex,
CC       at least composed of BRCA1, BARD1, UIMC1/RAP80, ABRAXAS1, BRCC3/BRCC36,
CC       BABAM2 and BABAM1/NBA1. Interacts (via the BRCT domains) with ABRAXAS1
CC       (phosphorylated form); this is important for recruitment to sites of
CC       DNA damage. Can form a heterotetramer with two molecules of ABRAXAS1
CC       (phosphorylated form). Component of the BRCA1-RBBP8 complex. Interacts
CC       (via the BRCT domains) with RBBP8 ('Ser-327' phosphorylated form); the
CC       interaction ubiquitinates RBBP8, regulates CHEK1 activation, and
CC       involves RBBP8 in BRCA1-dependent G2/M checkpoint control on DNA
CC       damage. Associates with RNA polymerase II holoenzyme. Interacts with
CC       SMC1A, NELFB, DCLRE1C, CLSPN. CHEK1, CHEK2, BAP1, BRCC3, UBXN1 and
CC       PCLAF. Interacts (via BRCT domains) with BRIP1 (phosphorylated form).
CC       Interacts with FANCD2 (ubiquitinated form). Interacts with H2AX
CC       (phosphorylated on 'Ser-140'). Interacts (via the BRCT domains) with
CC       ACACA (phosphorylated form); the interaction prevents dephosphorylation
CC       of ACACA. Part of a BRCA complex containing BRCA1, BRCA2 and PALB2.
CC       Interacts directly with PALB2; the interaction is essential for its
CC       function in HRR. Interacts directly with BRCA2; the interaction occurs
CC       only in the presence of PALB2 which serves as the bridging protein.
CC       Interacts (via the BRCT domains) with LMO4; the interaction represses
CC       the transcriptional activity of BRCA1. Interacts (via the BRCT domains)
CC       with CCAR2 (via N-terminus); the interaction represses the
CC       transcriptional activator activity of BRCA1 (By similarity). Interacts
CC       with EXD2 (By similarity). Interacts (via C-terminus) with DHX9; this
CC       interaction is direct and links BRCA1 to the RNA polymerase II
CC       holoenzyme (By similarity). Interacts with DNA helicase ZGRF1; the
CC       interaction is increased following DNA damage induction (By
CC       similarity). {ECO:0000250|UniProtKB:P38398,
CC       ECO:0000269|PubMed:12360400}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P38398}.
CC       Chromosome {ECO:0000269|PubMed:22549958, ECO:0000269|PubMed:23039116}.
CC       Cytoplasm {ECO:0000250|UniProtKB:P38398}. Note=Localizes at sites of
CC       DNA damage at double-strand breaks (DSBs); recruitment to DNA damage
CC       sites is mediated by the BRCA1-A complex. Translocated to the cytoplasm
CC       during UV-induced apoptosis. {ECO:0000250|UniProtKB:P38398}.
CC   -!- TISSUE SPECIFICITY: In the embryo, expressed in otic vesicles at day
CC       9.5. At day 10.5, this expression decreases and high levels are found
CC       in the neuroectoderm. At days 11-12.5, high levels in differentiating
CC       keratinocytes and whisker pad primordia. At days 14-17, expression also
CC       observed in kidney epithelial cells. In the adult, highest levels found
CC       in spleen, thymus, lymph nodes, epithelial organs, and alveolar and
CC       ductal epithelial cells of the mammary gland. Very low levels in brain,
CC       kidney, and skin. No expression in heart, liver or lung.
CC   -!- DEVELOPMENTAL STAGE: In the mammary gland, expression increases
CC       dramatically during pregnancy. Levels fall during lactation and
CC       increase again during post-lactational regression of the mammary gland.
CC   -!- DOMAIN: The BRCT domains recognize and bind phosphorylated pSXXF motif
CC       on proteins. The interaction with the phosphorylated pSXXF motif of
CC       ABRAXAS1, recruits BRCA1 at DNA damage sites.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- DOMAIN: The RING-type zinc finger domain interacts with BAP1.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- PTM: Phosphorylated in response to IR, UV, and various stimuli that
CC       cause checkpoint activation, probably by ATM or ATR. Phosphorylation at
CC       Ser-971 by CHEK2 regulates mitotic spindle assembly. Phosphorylation by
CC       AURKA regulates centrosomal microtubule nucleation.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- PTM: Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination.
CC       'Lys-6'-linked polyubiquitination does not promote degradation.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U31625; AAB17114.1; -; mRNA.
DR   EMBL; U35641; AAB17113.1; -; mRNA.
DR   EMBL; U32446; AAA96393.1; -; mRNA.
DR   EMBL; U36475; AAC52323.1; -; mRNA.
DR   EMBL; AL590996; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U33835; AAA99742.1; -; Genomic_DNA.
DR   CCDS; CCDS25474.1; -.
DR   PIR; I49350; I49350.
DR   RefSeq; NP_033894.3; NM_009764.3.
DR   RefSeq; XP_030101355.1; XM_030245495.2.
DR   PDB; 7K3S; NMR; -; A=1337-1388.
DR   PDBsum; 7K3S; -.
DR   AlphaFoldDB; P48754; -.
DR   SMR; P48754; -.
DR   BioGRID; 198383; 47.
DR   ComplexPortal; CPX-4701; BRCA1-BARD1 complex.
DR   ComplexPortal; CPX-972; BRCC ubiquitin ligase complex.
DR   DIP; DIP-41981N; -.
DR   FunCoup; P48754; 1924.
DR   IntAct; P48754; 21.
DR   MINT; P48754; -.
DR   STRING; 10090.ENSMUSP00000017290; -.
DR   GlyGen; P48754; 1 site.
DR   iPTMnet; P48754; -.
DR   PhosphoSitePlus; P48754; -.
DR   jPOST; P48754; -.
DR   PaxDb; 10090-ENSMUSP00000017290; -.
DR   PeptideAtlas; P48754; -.
DR   ProteomicsDB; 273840; -.
DR   Pumba; P48754; -.
DR   Antibodypedia; 4527; 2266 antibodies from 46 providers.
DR   DNASU; 12189; -.
DR   Ensembl; ENSMUST00000017290.11; ENSMUSP00000017290.5; ENSMUSG00000017146.13.
DR   GeneID; 12189; -.
DR   KEGG; mmu:12189; -.
DR   UCSC; uc007lpd.2; mouse.
DR   AGR; MGI:104537; -.
DR   CTD; 672; -.
DR   MGI; MGI:104537; Brca1.
DR   VEuPathDB; HostDB:ENSMUSG00000017146; -.
DR   eggNOG; KOG4362; Eukaryota.
DR   GeneTree; ENSGT00440000034289; -.
DR   HOGENOM; CLU_002290_0_0_1; -.
DR   InParanoid; P48754; -.
DR   OMA; ATCQQSP; -.
DR   OrthoDB; 6105938at2759; -.
DR   PhylomeDB; P48754; -.
DR   Reactome; R-MMU-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-MMU-5685938; HDR through Single Strand Annealing (SSA).
DR   Reactome; R-MMU-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-MMU-5689901; Metalloprotease DUBs.
DR   Reactome; R-MMU-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-MMU-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates.
DR   Reactome; R-MMU-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-MMU-5693579; Homologous DNA Pairing and Strand Exchange.
DR   Reactome; R-MMU-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-MMU-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-MMU-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-MMU-69473; G2/M DNA damage checkpoint.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 12189; 27 hits in 122 CRISPR screens.
DR   ChiTaRS; Brca1; mouse.
DR   PRO; PR:P48754; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   RNAct; P48754; protein.
DR   Bgee; ENSMUSG00000017146; Expressed in secondary oocyte and 233 other cell types or tissues.
DR   ExpressionAtlas; P48754; baseline and differential.
DR   GO; GO:0070531; C:BRCA1-A complex; NAS:ComplexPortal.
DR   GO; GO:0070532; C:BRCA1-B complex; ISO:ComplexPortal.
DR   GO; GO:0031436; C:BRCA1-BARD1 complex; ISS:UniProtKB.
DR   GO; GO:0070533; C:BRCA1-C complex; ISO:ComplexPortal.
DR   GO; GO:0005813; C:centrosome; TAS:UniProtKB.
DR   GO; GO:0005694; C:chromosome; IDA:UniProtKB.
DR   GO; GO:0000793; C:condensed chromosome; IDA:MGI.
DR   GO; GO:0000794; C:condensed nuclear chromosome; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:1990391; C:DNA repair complex; IEA:Ensembl.
DR   GO; GO:0000800; C:lateral element; ISO:MGI.
DR   GO; GO:0001673; C:male germ cell nucleus; IDA:MGI.
DR   GO; GO:0016604; C:nuclear body; IEA:Ensembl.
DR   GO; GO:0000152; C:nuclear ubiquitin ligase complex; ISO:ComplexPortal.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISO:ComplexPortal.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; ISO:MGI.
DR   GO; GO:1990904; C:ribonucleoprotein complex; ISO:MGI.
DR   GO; GO:0001741; C:XY body; IDA:MGI.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0002039; F:p53 binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; ISO:MGI.
DR   GO; GO:0070063; F:RNA polymerase binding; ISS:UniProtKB.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0071681; P:cellular response to indole-3-methanol; IEA:Ensembl.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; ISO:ComplexPortal.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0007098; P:centrosome cycle; IGI:MGI.
DR   GO; GO:0051298; P:centrosome duplication; TAS:UniProtKB.
DR   GO; GO:0043009; P:chordate embryonic development; IMP:MGI.
DR   GO; GO:0007059; P:chromosome segregation; IEA:Ensembl.
DR   GO; GO:0006974; P:DNA damage response; IMP:MGI.
DR   GO; GO:0006281; P:DNA repair; NAS:ComplexPortal.
DR   GO; GO:0110025; P:DNA strand resection involved in replication fork processing; NAS:ComplexPortal.
DR   GO; GO:0006302; P:double-strand break repair; IMP:CACAO.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IEA:Ensembl.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0035825; P:homologous recombination; NAS:ComplexPortal.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; ISO:MGI.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IEA:Ensembl.
DR   GO; GO:0044818; P:mitotic G2/M transition checkpoint; IMP:MGI.
DR   GO; GO:0030308; P:negative regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IEA:Ensembl.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0045717; P:negative regulation of fatty acid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0044027; P:negative regulation of gene expression via chromosomal CpG island methylation; IDA:BHF-UCL.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0045787; P:positive regulation of cell cycle; NAS:ComplexPortal.
DR   GO; GO:0045739; P:positive regulation of DNA repair; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IEA:Ensembl.
DR   GO; GO:0006301; P:postreplication repair; IEA:Ensembl.
DR   GO; GO:0051865; P:protein autoubiquitination; ISS:UniProtKB.
DR   GO; GO:0085020; P:protein K6-linked ubiquitination; ISS:UniProtKB.
DR   GO; GO:0060816; P:random inactivation of X chromosome; IGI:MGI.
DR   GO; GO:2000001; P:regulation of DNA damage checkpoint; NAS:ComplexPortal.
DR   GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   CDD; cd17735; BRCT_BRCA1_rpt1; 1.
DR   CDD; cd17721; BRCT_BRCA1_rpt2; 1.
DR   CDD; cd16498; RING-HC_BRCA1; 1.
DR   FunFam; 3.30.40.10:FF:000213; Breast cancer type 1 susceptibility protein homolog; 1.
DR   FunFam; 3.40.50.10190:FF:000006; Breast cancer type 1 susceptibility protein homolog; 1.
DR   FunFam; 3.40.50.10190:FF:000025; Breast cancer type 1 susceptibility protein homolog; 1.
DR   Gene3D; 3.40.50.10190; BRCT domain; 2.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR011364; BRCA1.
DR   InterPro; IPR031099; BRCA1-associated.
DR   InterPro; IPR025994; BRCA1_serine_dom.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR036420; BRCT_dom_sf.
DR   InterPro; IPR018957; Znf_C3HC4_RING-type.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR13763:SF0; BREAST CANCER TYPE 1 SUSCEPTIBILITY PROTEIN; 1.
DR   PANTHER; PTHR13763; BREAST CANCER TYPE 1 SUSCEPTIBILITY PROTEIN BRCA1; 1.
DR   Pfam; PF00533; BRCT; 2.
DR   Pfam; PF12820; BRCT_assoc; 1.
DR   Pfam; PF00097; zf-C3HC4; 1.
DR   PIRSF; PIRSF001734; BRCA1; 1.
DR   PRINTS; PR00493; BRSTCANCERI.
DR   SMART; SM00292; BRCT; 2.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF52113; BRCT domain; 2.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   PROSITE; PS50172; BRCT; 2.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
DR   TreeFam; TF105060; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Cell cycle; Chromosome; Cytoplasm;
KW   DNA damage; DNA recombination; DNA repair; DNA-binding;
KW   Fatty acid biosynthesis; Fatty acid metabolism; Isopeptide bond;
KW   Lipid biosynthesis; Lipid metabolism; Metal-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Transferase; Tumor suppressor; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..1812
FT                   /note="Breast cancer type 1 susceptibility protein homolog"
FT                   /id="PRO_0000055832"
FT   DOMAIN          1585..1679
FT                   /note="BRCT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   DOMAIN          1698..1797
FT                   /note="BRCT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   ZN_FING         24..65
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          165..198
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          321..362
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          492..581
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          640..767
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          864..899
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          947..995
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1030..1056
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1147..1185
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1205..1230
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1244..1289
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1313..1343
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1353..1380
FT                   /note="Interaction with PALB2"
FT                   /evidence="ECO:0000250"
FT   REGION          1437..1547
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        165..176
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        321..332
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        352..362
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        538..556
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        557..572
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        669..679
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        702..733
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        758..767
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        947..972
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        973..991
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1151..1166
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1175..1185
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1255..1279
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1313..1323
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1333..1343
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1492..1504
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1527..1538
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         114
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         392
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         686
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         706
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         717
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         831
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         971
FT                   /note="Phosphoserine; by CHEK2"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         992
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1152
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1154
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1174
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1180
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1241
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1297
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1303
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1343
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1350
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1413
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1481
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1495
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        109
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        298
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        336
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        440
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        456
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        512
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        1048
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CONFLICT        93
FT                   /note="F -> L (in Ref. 3; AAA96393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        305
FT                   /note="S -> T (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        319
FT                   /note="A -> P (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        377
FT                   /note="Q -> E (in Ref. 3; AAA96393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        550
FT                   /note="K -> Q (in Ref. 3; AAA96393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        652
FT                   /note="P -> A (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        765
FT                   /note="S -> P (in Ref. 3; AAA96393 and 4; AAC52323)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        917
FT                   /note="P -> L (in Ref. 3; AAA96393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        933
FT                   /note="C -> S (in Ref. 3; AAA96393 and 7; AAA99742)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1091
FT                   /note="C -> R (in Ref. 1; AAB17114)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1122
FT                   /note="I -> K (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1206
FT                   /note="S -> R (in Ref. 3; AAA96393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1212..1213
FT                   /note="RM -> GI (in Ref. 3; AAA96393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1255
FT                   /note="S -> R (in Ref. 3; AAA96393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1261
FT                   /note="H -> N (in Ref. 3; AAA96393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1264
FT                   /note="A -> V (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1269
FT                   /note="A -> P (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1283
FT                   /note="K -> T (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1337
FT                   /note="N -> T (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1349
FT                   /note="T -> P (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1352..1353
FT                   /note="QR -> EG (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1381
FT                   /note="P -> S (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1390
FT                   /note="A -> G (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1400
FT                   /note="D -> V (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1503
FT                   /note="Q -> E (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1549
FT                   /note="A -> V (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1680
FT                   /note="K -> T (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1712
FT                   /note="E -> D (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1721
FT                   /note="E -> D (in Ref. 2; AAB17113)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1791
FT                   /note="D -> G (in Ref. 1; AAB17114)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1346..1348
FT                   /evidence="ECO:0007829|PDB:7K3S"
FT   HELIX           1350..1377
FT                   /evidence="ECO:0007829|PDB:7K3S"
FT   TURN            1378..1382
FT                   /evidence="ECO:0007829|PDB:7K3S"
SQ   SEQUENCE   1812 AA;  198795 MW;  2B47FB55B149FD71 CRC64;
     MDLSAVQIQE VQNVLHAMQK ILECPICLEL IKEPVSTKCD HIFCKFCMLK LLNQKKGPSQ
     CPLCKNEITK RSLQGSTRFS QLAEELLRIM AAFELDTGMQ LTNGFSFSKK RNNSCERLNE
     EASIIQSVGY RNRVRRLPQV EPGNATLKDS LGVQLSNLGI VRSVKKNRQT QPRKKSVYIE
     LDSDSSEETV TKPGDCSVRD QELLQTAPQE AGDEGKLHSA EEAACEFSEG IRNIEHHQCS
     DDLNPTENHA TERHPEKCQS ISISNVCVEP CGTDAHASSL QPETSSLLLI EDRMNAEKAE
     FCNKSKQPGI AVSQQSRWAA SKGTCNDRQV PSTGEKVGPN ADSLSDREKW THPQSLCPEN
     SGATTDVPWI TLNSSVQKVN EWFSRTGEML TSDSASARRH ESNAEAAVVL EVSNEVDGGF
     SSSRKTDLVT PDPHHTLMCK SGRDFSKPVE DNISDKIFGK SYQRKGSRPH LNHVTEIIGT
     FITEPQITQE QPFTNKLKRK RSTSLQPEDF IKKADSAGVQ RTPDNINQGT DLMEPNEQAV
     STTSNCQENK IAGSNLQKEK SAHPTESLRK EPASTAGAKS ISNSVSDLEV ELNVHSSKAP
     KKNRLRRKSS IRCALPLEPI SRNPSPPTCA ELQIDSCGSS EETKKNHSNQ QPAGHLREPQ
     LIEDTEPAAD AKKNEPNEHI RKRRASDAFP EEKLMNKAGL LTSCSSPRKS QGPVNPSPQR
     TGTEQLETRQ MSDSAKELGD RVLGGEPSGK TTDRSEESTS VSLVSDTDYD TQNSVSVLDA
     HTVRYARTGS AQCMTQFVAS ENPKELVHGS NNAGSGTEGL KPPLRHALNL SQEKVEMEDS
     ELDTQYLQNT FQVSKRQSFA LFSKPRSPQK DCAHSVPSKE LSPKVTAKGK QKERQGQEEF
     EISHVQAVAA TVGLPVPCQE GKLAADTMCD RGCRLCPSSH YRSGENGLSA TGKSGISQNS
     HFKQSVSPIR SSIKTDNRKP LTEGRFERHT SSTEMAVGNE NILQSTVHTV SLNNRGNACQ
     EAGSGSIHEV CSTGDSFPGQ LGRNRGPKVN TVPPLDSMQP GVCQQSVPVS DKYLEIKKQE
     GEAVCADFSP CLFSDHLEQS MSGKVFQVCS ETPDDLLDDV EIQGHTSFGE GDIMERSAVF
     NGSILRRESS RSPSPVTHAS KSQSLHRASR KLESSEESDS TEDEDLPCFQ HLLSRISNTP
     ELTRCSSAVT QRMPEKAEGT QAPWKGSSSD CNNEVIMIEA SQEHQFSEDP RCSGSMFSSQ
     HSAAQGSTAN ANSQDSNFIP PSKQRSHQCG NEEAFLSDKE LISDNEEMAT CLEEDNDQEE
     DSIIPDSEAS GYESETNLSE DCSQSDILTT QQRATMKYNL IKLQQEMAHL EAVLEQRGNQ
     PSGHSPSLLA DPCALEDLPD LEPNMSGAAI LTSKNINENP VSQNLKSACD DKFQLQHLEG
     PTSGDDESGM GRPSPFKSPL AGSRGSAHGC SRHLQKRNSP SQEELLQPAG SEASSEPHNS
     TGQSCLPRRE LEGTPYLGSG ISLFSSRDPE SESPKEPAHI GTTPASTSAL KIPQGQVAFR
     SAAAAGADKA VVGIVSKIKP ELTSSEERAD RDISMVVSGL TPKEVMTVQK FAEKYRLTLT
     DAITEETTHV IIKTDAEFVC ERTLKYFLGI AGGKWIVSYS WVVRSIQERR LLNVHEFEVK
     GDVVTGRNHQ GPRRSRESRE KLFKGLQVYC CEPFTNMPKD ELERMLQLCG ASVVKELPSL
     THDTGAHLVV IVQPSAWTED SNCPDIGQLC KARLVMWDWV LDSLSSYRCR DLDAYLVQNI
     TCDSSEPQDS ND
//
